NQO2 is a reactive oxygen species generating off-target for acetaminophen by Miettinen, Teemu P. & Björklund, Mikael
                                                              
University of Dundee
NQO2 is a reactive oxygen species generating off-target for acetaminophen








Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Miettinen, T. P., & Björklund, M. (2014). NQO2 is a reactive oxygen species generating off-target for
acetaminophen. Molecular Pharmaceutics, 11(12), 4395-4404. 10.1021/mp5004866
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 18. Mar. 2016
NQO2 Is a Reactive Oxygen Species Generating Off-Target for
Acetaminophen
Teemu P. Miettinen* and Mikael Björklund*
Division of Cell and Developmental Biology, College of Life Sciences, University of Dundee, DD1 5EH Dundee, Scotland, U.K.
*S Supporting Information
ABSTRACT: The analgesic and antipyretic compound acetaminophen (paracetamol)
is one of the most used drugs worldwide. Acetaminophen overdose is also the most
common cause for acute liver toxicity. Here we show that acetaminophen and many
structurally related compounds bind quinone reductase 2 (NQO2) in vitro and in live
cells, establishing NQO2 as a novel off-target. NQO2 modulates the levels of
acetaminophen derived reactive oxygen species, more specifically superoxide anions, in
cultured cells. In humans, NQO2 is highly expressed in liver and kidney, the main sites
of acetaminophen toxicity. We suggest that NQO2 mediated superoxide production may function as a novel mechanism
augmenting acetaminophen toxicity.
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■ INTRODUCTION
Acetaminophenalso known as paracetamol, Tylenol, and
acetyl-p-aminophenol (APAP)is possibly the most used drug
in the world, with around 50 million weekly users in the US
alone.1 Originally cyclooxygenase (COX) enzymes, the classical
target of nonsteroidal anti-inflammatory drugs, were considered
the “on-target” for acetaminophen. However, the evidence for
this remains controversial (reviewed in ref 2), and other
proteins, such as transient receptor potential cation channel,
member A1 (TRPA1), have been recently suggested to mediate
the therapeutic effects via acetaminophen metabolites.3 Direct
targets of acetaminophen have remained elusive as research has
focused on downstream events following acetaminophen
metabolism.4
Although acetaminophen is safe at low doses, overdose is the
leading cause of acute liver failure.2,5 This toxicity is considered
a very complicated and incompletely understood process that
takes place mainly in the liver and kidneys but involves several
cell types, including hepatocytes and cells of the immune
system (reviewed in refs 4−6). At the molecular level the two
main factors in acetaminophen toxicity are formation of a
highly reactive metabolite N-acetyl-p-benzoquinone imine
(NAPQI) and production of reactive oxygen species (ROS),
especially superoxide anions.7−11 These events are considered
separate, although they both center on mitochondria.4 The
reactive oxygen species and NAPQI are largely counteracted by
glutathione in the early stages of toxicity.4,5 However, after
glutathione depletion, NAPQI forms protein adducts and
damages mitochondria, which are considered as the main
source of superoxide in later stages of toxicity.4,9,10,12,13
Formation of NAPQI is essential for toxicity,14,15 but it alone
may be insufficient for causing necrotic cell death.16,17
Production of ROS can activate c-Jun N-terminal kinase
(JNK) and transient receptor potential melanostatine 2
(TRPM2) Ca2+ channels leading into further mitochondrial
damage and amplified ROS formation.4,6,16,18 Changes in
cytosolic Ca2+ levels have been observed early in hepatotox-
icity,11,13 and TRPM2 channels have been recently shown to
mediate acetaminophen hepatotoxicity.16 It is believed that an
initial oxidative stress may be needed for the activation of JNK
and Ca2+ channels.4,6 However, NAPQI mediated mitochon-
drial toxicity and ROS formation should only take place after
glutathione depletion, and oxidative stress, which is commonly
measured by indirect indicators of ROS, is not considered to
take place early in toxicity.7,9 Interestingly, recent advances in
live oxidative stress monitoring in vivo have observed excess
ROS formation almost immediately after acetaminophen
overdose.19 This early ROS formation was only seen with
high acetaminophen doses. Importantly, the molecular source
and cell type of origin for the initial ROS remains unclear.4
Here we show that the cytosolic protein quinone reductase 2
(NQO2) is a novel off-target for acetaminophen and many
acetaminophen-like compounds. NQO2, which is highly
expressed in human liver and kidneys, mediates acetaminophen
induced superoxide production in cultured cells.
■ EXPERIMENTAL SECTION
Small Molecules and NQO Proteins. Imatinib mesylate,
NMEH (1-methyl-1,4-dihydronicotinamide) and MnTBAP
chloride were from Santa Cruz Biotechnology. All other
compounds, including acetaminophen (meets USP testing
specifications, 98.0−101.0%) and its analogues, were from
Sigma-Aldrich unless stated otherwise. Acetaminophen and its
analogues were diluted in DMSO, which alone served as a
vehicle in all experiments, except when indicated otherwise.
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Recombinant DT diaphorase (NQO1) and NQO2 (both
human enzymes) were from Sigma-Aldrich. For thermal shift
assays involving APAP analogues, a His6-tagged NQO2
(human) expressed in Escherichia coli BL21(DE3) was used.
Acetaminophen Target Affinity Purification. Acetami-
nophen affinity column was prepared by coupling 5 mM 4-
acetamidothiophenol (Sigma-Aldrich) to SulfoLink coupling
gel (Pierce) in 10 mM Tris-HCl, 5 mM EDTA, 25 mM TCEP,
pH 8.5. A control column was prepared by omitting 4-
acetamidothiophenol. The column was blocked with 20 mM β-
mercaptoethanol. One gram of mouse liver was homogenized
in 10 mL of PBS containing 1% Triton X-100, 1 mM DTT, and
1× proteinase inhibitor cocktail (Sigma) and batch purified
using 1 mL of affinity matrix. Columns were washed with lysis
buffer and eluted with 20 mM acetaminophen. Eluted proteins
were concentrated by trichloroacetic acid/acetone precipitation,
separated on 4−12% SDS−PAGE, and stained with colloidal
Coomassie followed by mass spectrometry identification.
In Vitro Thermal Shift Assays. Thermal shift assays were
performed as described.20 Briefly, 5 μM NQO1 or NQO2, 5×
SYPRO orange (Sigma-Aldrich), and indicated chemicals were
mixed in buffer (10 mM Hepes, 150 mM NaCl, pH 7.5) on ice
with final sample volume of 50 μL. DMSO was used as solvent
for all chemicals with final DMSO concentration of 1% (w/v).
Sample temperature was increased 1 °C/min, and fluorescence
(λex = 470 nm; λem = 520 nm) was measured using Eppendorf
Mastercycler ep realplex2 thermal cycler.
Cell Culture Based Experiments. Cell culture, counting,
and fluorescence measurements were done essentially as in ref
21. HeLa cells were cultured in high glucose DMEM
supplemented with 10% FBS (Sigma-Aldrich), 1% L-glutamine,
and 1% Pen Strep. All experiments were done before cells
reached confluency. Cell counting and fluorescence measure-
ments were done using an Accuri C6 cytometer (Becton-
Dickinson) so that only cells of viable size were included in the
analysis. For measuring superoxide levels, MitoSOX Red (Life
Technologies) was added to 5 μM final concentration for 30
min, after which cells were washed twice with PBS and analyzed
with a flow cytometer. For measuring Ca2+ levels, Fluo-3
(Sigma-Aldrich) was added to 5 μM final concentration for 30
min followed by an additional 30 min with 1 mM probenecid
(Sigma-Aldrich), after which cells were collected and analyzed
as with MitoSOX measurements. Cell viability was assessed by
counting cell number and measuring membrane integrity as
descripted below for CETSA experiments.
RNAi was performed by reverse-transfecting with 40 nM
siRNA with HiPerfect (Qiagen). NQO2 (cat. no.
HSC.RNAI.N000904.12.1 and HSC.RNAI.N000904.12.7) and
NC1 negative control siRNAs were from Integrated DNA
Technologies (IDT). For overexpressions human codon
optimized NQO2 (GeneArt) was Gateway cloned into
pDEST40 vector containing 3xV5 tag in C terminus. Plasmids
(3 μg of plasmid per well on a 12-well plate) were transfected
with FuGENE HD (Promega).
For Western blots, antibodies were used at their recom-
mended concentrations and detected using infrared-dye
conjugated secondary antibodies and LICOR Odyssey
detection system. Antibodies used were GAPDH (#5174)
from Cell Signaling Technology, SOD1 (HPA001401) from
Sigma-Aldrich, and NQO2 (NBP1-31563) from Novus Bio-
logicals. All cell culture experiments were done before cells
reached confluency.
Cellular Thermal Shift Assay (CETSA). CETSA was
performed as in ref 22 with minor modifications and with
addition of a loading control. HeLa cells were trypsinized,
washed with PBS, and suspended in PBS supplemented with
protease inhibitor cocktail (Sigma-Aldrich). The cell suspension
(5000 cells/μL) was treated with compounds in DMSO (final
concentration not exceeding 0.5% (w/v)) for 1 h at 37 °C with
gentle mixing. Each sample (70 μL) was then heated at the
indicated temperature for 3 min using an Eppendorf
Thermomixer with mixing (500 rpm) and lysed with three
freeze−thaw cycles using dry ice and a 42 °C water bath. Cell
lysates were centrifuged at 16000g for 15 min at 4 °C, and
analyzed by Western blotting. For quantitation, band intensities
were normalized to the mean of the three lowest temperature
bands, in which protein levels stayed constant, and then NQO2
bands were normalized to SOD1 bands used as loading control.
ITDRFCETSA experiments were done using constant temper-
ature of 72 °C. Band intensities were normalized to the highest
concentration and SOD1 levels.
For analysis of cellular membrane integrity and cell viability,
cells were heated as the CETSA samples, followed by 10 min
incubation with 30 μg/mL propidium iodide and analysis by
flow cytometry.
Analysis of NQO2 Binding Site. Acetaminophen binding
to NQO2 structure (PDB: 1ZX1) was modeled with
DockingServer (www.dockingserver.com) using default param-
eters of the program. Acetaminophen binding to the NQO2
active site was measured using electronic absorption spectros-
copy essentially as described.23 Briefly, 2 mg/mL His6-NQO2
was mixed with 0.5 mM acetaminophen or DMSO in 25 mM
Hepes, 150 mM NaCl, pH 7.5, and absorption spectra were
measured between 250 and 550 nm. The absorption spectrum
of free FAD (100 μM) with 5 mM acetaminophen or DMSO
was measured as a control.
Enzyme Assays. NQO1 and NQO2 inhibition was
measured by mixing 50 μL of 50 mM Hepes-KOH, pH 7.4,
with 0.01% Tween20, 0.18 mg/mL BSA, and 1 μM FAD
containing 100 ng of recombinant NQO1 or NQO2 (Sigma-
Aldrich) and mixing with 50 μL of the same buffer with test
compounds. Reactions were initiated by adding 50 μL of assay
buffer containing 50 mM Hepes-KOH, pH 7.4, with 0.01%
Tween20, 0.18 mg/mL BSA, 1 μM FAD, and 500 μM NADH
(for NQO1) or 500 μM NMEH (for NQO2) as cosubstrates as
well as 600 μM MTT and 300 μM menadione. The absorbance
of the samples was measured at 595 nm.
Substrate assays were performed similarly to inhibition assays
except omitting the menadione substrate. For kinetic assays
acetaminophen and menadione were diluted directly into the
reaction mix in order to omit DMSO as DMSO alone yields
some background activity. Absorbance was measured every 30 s
after the reaction was started and background correction was
made using a sample without NQO2. All samples were
measured simultaneously in a 96-well assay format.
NQO2 Expression in Human Tissues. Human Normal
Tissue Blot II was obtained from ProSci Incorporated (Poway,
CA) and stained with NQO2 antibody. Each lane contains
same amount of total protein (15 μg). NQO2 mRNA
expression levels are from Illumina Body Map RNA-Seq data
(E-MTAB-513). An independent human skeletal muscle
sample was purchased from Abcam (ab29330).
Statistical Analysis. Western blot band intensities were
analyzed with ImageJ. Correlation values for Figure 1c were
calculated using logarithmic two parameter nonlinear regression
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equation in SigmaPlot. Sigmoidal curves were fitted to CETSA
and ITDRFCESTA data using SigmaPlot. For kinetic analysis,
ligand binding curves and confidence intervals were fitted and
Vmax, Km, and regression correlation (R
2) were analyzed using
SigmaPlot and its enzyme kinetics application. Statistical
significances were evaluated by ANOVA and two tailed t test
with Bonferroni correction (n.s. = nonsignificant, * = p < 0.05,
** = p < 0.01, *** = p < 0.001 in all figures and panels). All
data with error bars depict mean and standard deviation.
■ RESULTS
Acetaminophen Binds NQO2 in Vitro. We investigated
potential direct targets of acetaminophen by affinity purification
from a mouse liver lysate. To simplify the coupling chemistry,
we attached thioacetaminophen to sulforeactive affinity matrix
via thioether bond as chemical properties of ethers and
thioethers are very similar (Figure 1a). Proteins were eluted
with free acetaminophen. Despite high background in control
and thioacetaminophen columns, a protein of ∼25 kDa was
specifically observed in the thioacetaminophen column eluate
(Figure 1b). Mass spectrometry unambiguously identified this
protein with 92% sequence coverage as quinone reductase 2
(Supporting Information Figure S1), formally known as
NAD(P)H dehydrogenase, quinone 2 (NQO2), which is a
cytoplasmic protein also known as quinone reductase 2 (QR2).
NQO2/QR2 should not be confused with the mitochondrial
NQO2 (formally known as NDUFV2) involved in oxidative
phosphorylation. The binding of NQO2 to thioparacetamol
column was confirmed by Western blotting of the eluates
(Figure 1b, bottom).
Relatively little is known about NQO2, and the endogenous
substrates of NQO2 have remained largely elusive, although
dopamine has been suggested.24 NQO2 is known to be
important in drug metabolism,25 and NQO2 has been
associated with numerous disorders, including cancer and
neurodegenerative diseases.26 Exogenous substrates of NQO2
include menadione, and several inhibitors have been described,
for example, quercetin, resveratrol, and imatinib/Gleevec26−29
(see Supporting Information Figure S2 for structures). Despite
its name, NQO2 uses nonphosphorylated dihydronicotina-
mides and not NAD(P)H as its cosubstrate30 and NQO2
substrate specificity is not limited to quinones.25,26 NQO2
mediated metabolism can also generate free radicals when
appropriate substrates are available.31
Inverse pharmacological approaches have identified NQO2
as a binding partner for many interesting compounds such as
resveratrol, chloroquine, and melatonin.28,32,33 To validate
acetaminophen binding to NQO2 in vitro we performed
thermal shift assays using recombinant NQO2.20 Human
NQO2 was used in this and all subsequent assays.
Acetaminophen and its regioisomer 3-acetaminophenol
(AMAP) both stabilized NQO2 against thermal denaturation
in a concentration dependent manner (Figure 1c). Acetamino-
phen interaction was selective for NQO2 as no binding was
observed with the closely related NQO1 (DT-diaphorase,
Figure 1c), while a known inhibitor of NQO1, dicoumarol,
significantly stabilized this enzyme (Figure 1d). NQO2
inhibitors quercetin and resveratrol also caused substantial
thermal stabilization of NQO2 (Figure 1d). Analysis of all
regioisomers of acetaminophen indicated that the hydroxyl
group position is not critical for NQO2 binding (Figure 1d and
Supporting Information Table S1).
Optimized Cellular Thermal Shift Assay Reveals
NQO2-Acetaminophen Interaction in Live Cells. It is
well-known that in vitro assays represent cellular binding poorly,
as drug concentration and target engagement are dependent on
ADME properties (absorption, distribution, metabolism, and
excretion). To better reflect physiological binding conditions
inside cells, we performed cellular thermal shift assays
(CETSA) between acetaminophen and NQO2 in live HeLa
cells (Figure 2a).22 We improved the original method by
including superoxide dismutase 1 (SOD1) as a control protein.
SOD1 is a thermostable protein,34 and we did not observe any
significant reduction in SOD1 levels with CETSA treatment
temperatures up to 80 °C (Figure 2b). We also validated that
none of the compounds in our assay affected SOD1 levels
(Figure 2c). To validate that the observed bindings take place
inside intact cells, we measured cell membrane permeability
using cell impermeable propidium iodide staining. Although
membrane integrity was lost in the highest temperatures used,
in temperatures where NQO2 became destabilized membranes
remained intact (Figure 2d). We conclude that the binding
observed is taking place in intact cells and not just cell lysates.
Consistent with the in vitro thermal shift assays, treatment
with acetaminophen, AMAP, and quercetin stabilized NQO2 in
live HeLa cells (Figure 2e). To more quantitatively understand
the NQO2 binding affinity in living cells, we performed
isothermal dose response fingerprint analysis based CETSA
(ITDRFCETSA).
22 This assay indicated that the cellular binding
affinity of acetaminophen was ∼500 times weaker than that of
resveratrol and approximately 1 mM extracellular concentration
is required to observe binding under our experimental
conditions (Figure 2f).
Figure 1. Acetaminophen binds to NQO2. (a) Structures of
acetaminophen and thioacetaminophen coupled to affinity matrix.
(b) SDS−PAGE separation of protein eluates from thioacetaminophen
(+) and control (−) columns. NQO2 detection from Western blot of
the eluates is shown at bottom. (c) Thermal shift assays of APAP and
AMAP with NQO2 and APAP with NQO1. See panel d for controls.
(d) NQO2 thermal shift assay of acetaminophen regioisomers (2
mM), nitroacetanilide (2 mM), and NQO2 inhibitors quercetin (1
μM) and resveratrol (10 μM). AOAP is acetyl-o-aminophenol.
Dicoumarol (10 μM) control for NQO1 is shown (N = 3−4 in
panels c and d).
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Acetaminophen Binds NQO2 near the Active Site. We
next investigated acetaminophen binding to NQO2 in more
detail. The binding pocket of NQO2 is hydrophobic, and
known inhibitors of NQO2 have planar aromatic ring systems
(Supporting Information Figure S2), which bind adjacent to
the isoalloxazine ring of flavin adenine mononucleotide (FAD)
and are coordinated by aromatic amino acid residues in the
catalytic pocket.28 In silico docking to NQO2 suggested a
similar mode of binding for acetaminophen (Figures 3a and
3b). To validate this prediction, we utilized electronic
absorption spectroscopy, which has been used previously to
assess NQO2 composition and drug binding.23,29 The
absorption spectrum of NQO2 bound flavin (absorbance in
the 350−500 nm range) was affected by acetaminophen and its
regioisomers (Figure 3c and Supporting Information Figure S3)
in a similar manner to that observed with imatinib binding at
Figure 2. Cellular thermal shift assays of acetaminophen binding to NQO2. (a) Schematic presentation of CETSA. The interaction between drug
and target protein increases the thermal stability of the protein, which can be measured by separating and quantifying nonaggregated levels of the
target protein at different temperatures. (b) SOD1 levels in HeLa cells treated as for CETSA experiments. No significant changes in protein levels
were seen in the used temperatures. (c) SOD1 protein levels in cellular thermal shift samples. SOD1 levels did not change significantly when HeLa
cells were treated as in CETSA (left panel) or ITDRFCETSA (right panel) experiments. For the ITDRFCETSA experiment the second highest
concentration of each chemical was used, as samples reached maximal NQO2 intensity at this concentration. GAPDH was used as a loading control.
(d) HeLa cell count and membrane integrity after CETSA treatment. HeLa cells were treated as for CETSA, after which cells were treated with
propidium iodide for 15 min before analyzing membrane integrity and cell count using flow cytometer. Values are normalized to samples treated at
37 °C. (e) Cellular thermal shift assay of NQO2. APAP (10 mM), AMAP (10 mM), and quercetin (100 μM) were incubated with HeLa cells for 1 h.
Representative NQO2 Western blots of each sample are shown. NQO2 levels were normalized to SOD1 levels used as loading control (not shown).
Statistical significances between DMSO and APAP are indicated. Note that the membrane integrity is not maintained at the highest temperatures
(panel d), but NQO2 binding is observed already before this, indicating binding in intact cells. APAP and AMAP did not differ significantly. (f)
Isothermal (at 72 °C) dose response fingerprints in HeLa cells after 1 h exposure to APAP, nitroacetanilide, resveratrol, and menadione.
Representative NQO2 Western blots of each sample are shown. Statistical significance between APAP and nitroacetanilide with 0.5 mM
concentration is indicated (N = 3−4 in all panels).
Molecular Pharmaceutics Article
dx.doi.org/10.1021/mp5004866 | Mol. Pharmaceutics 2014, 11, 4395−44044398
the active site.23 We observed no effect of acetaminophen on
free FAD (Figure 3c, bottom right). The spectroscopy data
indicates that acetaminophen binds very close to FAD in the
active site. Further supporting this, thermal shifts caused by
quercetin and menadione, which both bind to the NQO2 active
site, were not additive with acetaminophen (Figure 3d). These
data suggest that acetaminophen binds NQO2 near the active
site similarly to known inhibitors, substrates, and cosubstrates.
To conclusively confirm the binding orientation of acetamino-
phen, cocrystallization of acetaminophen with NQO2 would be
required.
Acetaminophen Appears To Act as a Weak NQO2
Substrate. We next tested if acetaminophen inhibits NQO2.
However, NQO2 activity was not affected by acetaminophen or
AMAP (up to 10 mM), whereas known inhibitors of NQO2
potently inhibited NQO2 activity in an in vitro enzyme assay
(Figure 4a and Supporting Information Figure S4a). Similarly,
acetaminophen displayed no inhibitory effect on NQO1
(Supporting Information Figure S4b). We next considered
the possibility that acetaminophen might act as a substrate or
cosubstrate. No activity was observed when the assay
cosubstrate NMEH was replaced by acetaminophen, indicating
that acetaminophen is not a cosubstrate (Supporting
Information Figure S4c). Instead, NQO2 could utilize
acetaminophen and AMAP as weak substrates (Figure 4b).
This activity was abrogated by quercetin (Figure 4b), and no
substrate activity was seen with NQO1 (Supporting Informa-
tion Figure S4d), indicating a NQO2-dependent reaction.
Kinetic substrate analysis validated acetaminophen acting as a
weak NQO2 substrate with Km = 417 ± 10 μM compared to
Km = 4.3 ± 0.1 μM for menadione (Figure 3c). As the weak
substrate activity of acetaminophen could be potentially
explained by synthesis byproducts and/or degradation prod-
ucts, we tested if simple quinones and hydroquinones might
explain this activity. However, 4-benzonquinone and 4-
hydroquinone displayed no such activity in the NQO2 assay
(Supporting Information Figure S4e). Acetaminophen seems to
therefore function as a novel, albeit poor, NQO2 substrate,
although it is not clear what NQO2 modifies acetaminophen to.
Library of Acetaminophen-like Molecules Displays a
Wide Range of NQO2 Interactions and Correlating
Levels of Superoxide Production. Acetaminophen and
AMAP were not obvious candidates for possible NQO2
substrates based on previously known substrate structures.
We therefore extended our in vitro thermal shift and substrate
assays by screening 22 compounds with structural similarity to
acetaminophen (Supporting Information Figure S2). NQO2
could bind and utilize many acetaminophen analogues as
substrates (Supporting Information Table S1), and there was a
weak correlation between the binding and substrate assays
(Figure 5a, Supporting Information Table S1). Analogues with
acidic side chains display no NQO2 binding or substrate
activity. In contrast, nitroacetanilide had high binding affinity in
vitro (Figure 1d), and it displayed stronger NQO2 binding than
acetaminophen in ITDRFCETSA (Figure 2e).
NQO2 has been shown to be capable of producing ROS,31
and acetaminophen overdose causes extensive oxidative stress.
Most studies on acetaminophen induced ROS are done in vivo
and have therefore relied on indirect measurements of ROS,
like nitrosylation of tyrosine residues and lipid peroxidations,
which are only observable after ROS mediated damage
accumulates. To measure if acetaminophen interaction with
NQO2 could be involved in superoxide production, we used
MitoSOX fluorescence probe, which can react with both intra-
and extramitochondrial ROS and is most sensitive toward
superoxide. Importantly, acetaminophen induced MitoSOX
Figure 3. Acetaminophen binds to NQO2 active site. (a) In silico docking analysis of APAP to NQO2 (PDB: 1ZX1) indicates binding at the active
site adjacent to the isoalloxazine ring of flavin adenine mononucleotide (FAD). (b) Suggested interacting amino acids in NQO2 based on in silico
docking assays. (c) Electronic absorption spectroscopy of NQO2 with 0.5 mM APAP (red) and DMSO (blue). Inset on right top corner shows
difference spectrum, and inset on right bottom shows spectra with free FAD. (d) NQO2 thermal shifts of APAP (10 mM) with known NQO2 active
site binding molecules menadione (50 μM) and quercetin (1 μM) (N = 4).
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signal was fully reversed with the addition of superoxide
scavenger MnTBAP (Figure 5b). We used HeLa cells as a cell
culture model for NQO2 mediated ROS production as HeLa
cells express NQO2 and have relatively low baseline ROS levels
(data not shown). Furthermore, we did not observe superoxide
production in HeLa cells after treatment with NAPQI, and
acetaminophen induced superoxide levels were unaltered when
P450 enzymes required for NAPQI formation were inhibited
with disulfiram35 (Figures 5c and 5d), indicating that the ROS
formation by acetaminophen is largely separate from NAPQI
mediated damage in this cell culture model. Furthermore, to
focus on direct effects of acetaminophen, we used DMSO,
which inhibits acetaminophen metabolism and NAPQI
formation,4 as a solvent for acetaminophen. In summary, the
HeLa cell model is thus ideal to confirm binding and to
separate ROS effects from NAPQI mediated toxic effects.
Acetaminophen and its analogues displayed large differences
in superoxide production, and there was a positive correlation
(R2 = 0.499) between superoxide production in HeLa cells and
NQO2 substrate activity in vitro (Figure 5e, Supporting
Information Table S1). A notable exception was AMAP,
which did not increase superoxide levels although it clearly
binds NQO2 in cells (see Figure 2e). It has been suggested that
reactive metabolites of AMAP and APAP differ in their ability
to diffuse across mitochondrial membranes and arylate
mitochondrial matrix proteins.13 This data suggests that
NQO2 may be involved in acetaminophen induced superoxide
production, although other mechanisms must also exist to
explain the difference between AMAP and APAP.
NQO2 Is Highly Expressed in the Sites of Acetamino-
phen Toxicity. We next wanted to understand if there are
biological consequences for the NQO2 interaction. As relatively
little is known about NQO2, we examined the NQO2 protein
and mRNA expression levels in a panel of normal human
tissues. Although NQO2 was present in all tested tissues, the
levels were clearly highest in liver and kidney (Figure 6), the
main sites of acetaminophen toxicity. These findings are
consistent with previous observations in rat.36 We also observed
unreported NQO2 variants of approximately 35 kDa in the
skeletal muscle. However, these NQO2 variants may have been
partially donor specific as a similar NQO2 pattern was not seen
in an independent human skeletal muscle sample (Supporting
Information Figure S5).
NQO2 Levels Modulate Acetaminophen Induced
Superoxide Production and Ca2+ Levels. The correlation
between NQO2 substrate activity and superoxide production
with the acetaminophen-like compounds suggested that NQO2
might be involved in acetaminophen mediated ROS
production. To examine this we inhibited NQO2 with
quercetin, resveratrol, and imatinib. Acetaminophen induced
superoxide levels were significantly lower in the presence of all
these inhibitors in HeLa cells (Figure 7a, left). Although these
NQO2 inhibitors have off-target effects and possible anti-
oxidant effects, it seems more likely that these inhibitors reduce
superoxide through their common target, NQO2. To confirm
this, we inhibited NQO2 with two independent siRNAs and
similarly observed partial reduction in superoxide production
by acetaminophen (Figure 7b, middle). Knock-down efficiency
of NQO2 was approximately 50%, as measured by Western
blotting (Figure 7b, left), matching the reduction in superoxide
levels. Overexpression of NQO2 in HeLa cells resulted in a
significant increase in superoxide production by acetaminophen
(Figure 7c, middle), and this roughly correlated with the level
of NQO2 overexpression (Figure 7c, left).
Changes in both cytosolic and mitochondrial Ca2+ levels are
considered as one of the earliest signatures of acetaminophen
hepatotoxicity.11,13 As ROS levels may impact Ca2+ homeo-
stasis, we measured if NQO2 has an effect on acetaminophen
modulated Ca2+ homeostasis, as measured by the Ca2+ sensitive
fluorescence probe Fluo-3. Inhibition of NQO2 reduced the
changes in Ca2+ levels caused by acetaminophen (Figures 7a
and 7b, right). Although HeLa cells cannot be considered as a
suitable model for acetaminophen toxicity, both genetic and
chemical inhibition of NQO2 in HeLa cells resulted in a
modest protection from high doses of acetaminophen
(Supporting Information Figure S6). Altogether, this data
indicates that NQO2 activity can modulate superoxide
production and changes in Ca2+ levels induced by acetamino-
phen in HeLa cell culture.
■ DISCUSSION
Very few direct targets for acetaminophen are known.4 We have
identified NQO2 as an off-target for acetaminophen with a role
in superoxide production and modulation of Ca2+ levels in
cultured HeLa cells. While we have comprehensively validated
the binding of acetaminophen to NQO2 with several
independent methods in vitro, in mouse liver lysate, and in
cultured HeLa cells, all of the data indicates that this is a
relatively weak interaction and the in vivo significance of this
binding will require further studies. Although in our experi-
Figure 4. Acetaminophen functions as a weak substrate for NQO2. (a)
NQO2 in vitro inhibition assay. NQO2 was incubated in the presence
of compounds at the concentrations indicated and NQO2 activity
measured with a colorimetric assay. (b) NQO2 substrate assay.
Substrate activities of menadione (25 μM), APAP (2.5 mM), AMAP
(2.5 mM), and control (DMSO) are shown. All substrate activities
were abolished by addition of quercetin (10 μM). (c) Kinetic analysis
of NQO2 substrate activity with menadione (left) and acetaminophen
(right). Red lines represent 95% confidence intervals of the fitted
ligand binding curves (black). NQO2 activity was measured with
increasing substrate concentrations at fixed enzyme and cosubstrate
(500 μM NMEH) concentrations. Michaelis constants and maximum
reaction rates are displayed with standard errors. Note that
acetaminophen and menadione were dissolved in the assay buffer in
order to omit DMSO (N = 3 in all panels).
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ments acetaminophen did not inhibit NQO2 in vitro, our
results are consistent with previous findings that acetamino-
phen protects cells from menadione toxicity,37 possibly through
NQO2 substrate competition. Instead of NQO2 inhibition, we
observed that acetaminophen acts as a weak NQO2 substrate.
The substrate activity of acetaminophen was approximately
100-fold less than that of menadione, which is a highly active
NQO2 substrate.26 The thermal shift assay similarly suggested
that acetaminophen binding is >100-fold weaker than that of
menadione. Menadione toxicity requires both NQO1 and
NQO2 catalyzed metabolism, and in mice, the LD50 for
menadione is 13 mg/kg, but this depends on the cosubstrate
availability.38 For comparison, acetaminophen has an intra-
peritoneal LD50 ≈ 500 mg/kg. Thus, the difference in substrate
activity is slightly higher than the difference in the in vivo
toxicity, which may be because of assay conditions and due to
the well-known routes of acetaminophen toxicity.
Whereas most NQO2 binding compounds are inhibitors of
this enzyme, our observations suggesting that acetaminophen
acts as a weak NQO2 substrate propose a new metabolic route
for acetaminophen. Although it is theoretically possible that
NQO2 catalyzes a reaction between acetaminophen and
NAPQI,8,26 whether and exactly how NQO2 is involved in
acetaminophen metabolism in vivo remains unknown. Interest-
ingly, if NQO2 has a role in acetaminophen metabolism and
toxicity in vivo, the presence of NQO2 cosubstrates may
represent a source of variation in the individual responses to
acetaminophen.
We observed NQO2 mediated ROS production in HeLa
cells. Although superoxide is a very reactive molecule as such,
the cytotoxic effects of superoxide are attenuated through the
action of superoxide dismutases and only excessive amounts
overwhelming the capacity of the dismutases will result in
oxidative damage. Such cytotoxic concentrations are achieved
as a result of acetaminophen overdose.7−11 Although the
MitoSOX probe does not react exclusively with superoxide, the
acetaminophen induced ROS could be rescued with a
superoxide scavenger, suggesting that acetaminophen produces
Figure 5. Acetaminophen-like compounds display wide range of NQO2 substrate activity in vitro and correlating superoxide production in cultured
HeLa cells. (a) Comparison of NQO2 thermal shifts and NQO2 substrate activities for acetaminophen analogues (2 mM). Structures of some of the
analogues are shown for comparison. (b) Specificity of MitoSOX measurement. HeLa cells were treated with APAP (5 mM) for 2.5 h followed by
0.5 h treatment with superoxide scavenger, MnTBAP (200 μM). (c) Comparison of APAP and NAPQI mediated superoxide production. HeLa cells
were treated with APAP (2 mM) or NAPQI (20 μM) for 8 h. Note that only a small fraction of APAP is metabolized to NAPQI, and higher NAPQI
concentrations are lethal to cells. (d) Effect of P450 inhibition on APAP mediated superoxide production. HeLa cells were treated with P450
inhibitor disulfiram (2 μM) for 1 h followed by APAP treatment (5 mM) for 2 h. Data normalized to controls without APAP treatment for clarity.
(e) Comparison of NQO2 substrate activity and cellular superoxide production by acetaminophen and its analogues. For MitoSOX measurements
HeLa cells were treated with 2 mM chemicals for 1 h. See Supporting Information Figure S1 and Table S1 for structures and data, respectively (N =
3 in all panels).
Figure 6. NQO2 protein and mRNA levels in normal human tissues.
Tissue Western blot displays unknown NQO2 variants in skeletal
muscle. For quantifications, mRNA and protein levels were normalized
to NQO2 in liver. See also Supporting Information Figure S3.
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mainly superoxide in our model. This superoxide production
was also seen with many acetaminophen-like compounds that
display NQO2 substrate activity in vitro, supporting the
conclusion that NQO2 is a cellular source for acetaminophen
induced ROS. Furthermore, our screen of acetaminophen-like
compounds, some of which are also fragments of more specific
drugs,39 provides a basis for structure−activity studies to better
understand NQO2 function.
The low affinity binding between NQO2 and acetaminophen
suggests that NQO2 does not play an active role in the
therapeutic effects of acetaminophen. However, the pharmaco-
kinetics of acetaminophen result in very high plasma
concentrations, especially when compared to other known
NQO2 targeting chemicals, like resveratrol.2 With ITDRFCETSA
we detect an interaction between acetaminophen and NQO2
with approximately 1 mM extracellular concentrations of the
drug, which is in agreement with the in vitro substrate assay
with a Km value of ∼0.4 mM. Acetaminophen plasma
concentrations can reach up to 10 mM in overdose patients,40
and, at least in rodents, acetaminophen plasma and tissue
concentrations are known to be essentially the same.41 We also
observed that NQO2 is predominantly present in liver and
kidney, the tissues where acetaminophen is known to cause
toxicity. It seems therefore possible that NQO2 may have a role
in acetaminophen induced superoxide production also in vivo.
High levels of oxidant stress occur after most of the
acetaminophen has been metabolized in vivo, NAPQI mediated
damage and JNK kinase mediated amplification of ROS being
key events. Interestingly, JNK activation is considered to
require an initial ROS stimulus, although the source of this
stimulus in acetaminophen toxicity is unknown.2,4 In NQO2
knockout mouse keratinocytes JNK activation is abolished.42
We propose that acetaminophen may act in part through
NQO2 in the initial phase of toxicity, where increases in ROS
and cytosolic Ca2+ levels concomitant with glutathione
depletion are observed.13,19 If so, NQO2 mediated ROS
production would not necessarily be the main cause of toxicity
but rather a damage augmenting mechanism. This theory does
not contradict the current model of acetaminophen toxicity
where inhibition of NAPQI formation protects from
acetaminophen overdose,14 and N-acetyl cysteine, which is a
nonspecific ROS scavenger, reverses oxidative stress and
toxicity.10 Consistent with our observations, NQO2 inhibitors,
resveratrol and quercetin, have also been shown to alleviate
acetaminophen toxicity in mice.43,44 However, additional
studies are required to fully validate NQO2 inhibition as the
protective mechanism instead of antioxidant properties or
inhibition of NAPQI formation.4 Conclusive in vivo validation
that NQO2 participates in ROS production in early
acetaminophen toxicity would require live monitoring of
Figure 7. NQO2 is involved in acetaminophen induced superoxide production. (a) APAP induced superoxide production (left) and intracellular
Ca2+ levels (right) after chemical inhibition of NQO2. HeLa cells were treated with control (DMSO), quercetin (10 μM), resveratrol (10 μM), or
imatinib (20 μM) for 1 h followed by 4 h treatment with vehicle (DMSO), APAP (5 mM), or AMAP (5 mM). (b) APAP induced superoxide
production after NQO2 RNAi. HeLa cells were treated with control or NQO2 siRNA for 48 h followed by 4 h treatment with vehicle (DMSO),
APAP (5 mM), or AMAP (5 mM). (c) APAP induced superoxide production after NQO2 overexpression. HeLa cells were transfected with empty
vector or NQO2, incubated for 36 h followed by 5 h treatment with vehicle (DMSO) or APAP (5 mM). In panels b and c representative Western
blots of NQO2 levels are on the left, superoxide levels in the middle, and intracellular Ca2+ levels on the right. Data is normalized to each control for
clarity (N = 3−4 in all panels).
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ROS19 in NQO2 knockout animal model, which is beyond the
scope of this work.
Altogether, our findings broaden the spectrum of known
acetaminophen targets and suggest a potential new mechanism
through which acetaminophen can mediate its biological effects.
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AMAP, acetyl-m-aminophenol; AOAP, acetyl-o-aminophenol;
APAP, acetyl-p-aminophenol (acetaminophen); CETSA, cel-
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fingerprint analysis based CETSA; DMSO, dimethyl sulfoxide;
FAD, flavin adenine dinucleotide; MnTBAP, manganese(III)
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mide adenine dinucleotide (reduced form); NMEH, 1-methyl-
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NAD(P)H dehydrogenase, quinone 2; ROS, reactive oxygen
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